Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/9939
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Vann, K.R. | - |
dc.contributor.author | Ergün, Y. | - |
dc.contributor.author | Zencir, Sevil | - |
dc.contributor.author | Oncuoglu, S. | - |
dc.contributor.author | Osheroff, N. | - |
dc.contributor.author | Topcu, Z. | - |
dc.date.accessioned | 2019-08-16T13:07:55Z | |
dc.date.available | 2019-08-16T13:07:55Z | |
dc.date.issued | 2016 | - |
dc.identifier.issn | 0960-894X | - |
dc.identifier.uri | https://hdl.handle.net/11499/9939 | - |
dc.identifier.uri | https://doi.org/10.1016/j.bmcl.2016.02.034 | - |
dc.description.abstract | Ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole) is an antineoplastic agent that intercalates into DNA and alters topoisomerase II activity. Unfortunately, this compound displays a number of adverse properties. Therefore, to investigate new ellipticine-based compounds for their potential as topoisomerase II-targeted drugs, we synthesized two novel derivatives, N-methyl-5-demethyl ellipticine (ET-1) and 2-methyl-N-methyl-5-demethyl ellipticinium iodide (ET-2). As determined by DNA decatenation and cleavage assays, ET-1 and ET-2 act as catalytic inhibitors of human topoisomerase II? and are both more potent than the parent compound. Neither compound impairs the ability of the type II enzyme to bind its DNA substrate. Finally, the potency of ET-1 and ET-2 as catalytic inhibitors of topoisomerase II? appears to be related to their ability to intercalate into the double helix. © 2016 Elsevier Ltd | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier Ltd | en_US |
dc.relation.ispartof | Bioorganic and Medicinal Chemistry Letters | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Anticancer drugs | en_US |
dc.subject | Catalytic inhibitor | en_US |
dc.subject | DNA cleavage | en_US |
dc.subject | DNA intercalation | en_US |
dc.subject | DNA topoisomerase II? | en_US |
dc.subject | Ellipticine derivatives | en_US |
dc.subject | 2 methyl n methyl 5 demethyl ellipticinium iodide | en_US |
dc.subject | antineoplastic agent | en_US |
dc.subject | DNA topoisomerase (ATP hydrolysing) A | en_US |
dc.subject | ellipticine | en_US |
dc.subject | ellipticine derivative | en_US |
dc.subject | etoposide | en_US |
dc.subject | gyrase inhibitor | en_US |
dc.subject | kinetoplast DNA | en_US |
dc.subject | n methyl 5 demethyl ellipticine | en_US |
dc.subject | unclassified drug | en_US |
dc.subject | DNA | en_US |
dc.subject | DNA binding protein | en_US |
dc.subject | DNA topoisomerase (ATP hydrolysing) | en_US |
dc.subject | DNA topoisomerase II alpha | en_US |
dc.subject | intercalating agent | en_US |
dc.subject | tumor antigen | en_US |
dc.subject | Article | en_US |
dc.subject | catalysis | en_US |
dc.subject | controlled study | en_US |
dc.subject | drug potency | en_US |
dc.subject | drug protein binding | en_US |
dc.subject | drug synthesis | en_US |
dc.subject | enzyme activity | en_US |
dc.subject | enzyme inhibition | en_US |
dc.subject | human | en_US |
dc.subject | antagonists and inhibitors | en_US |
dc.subject | chemistry | en_US |
dc.subject | metabolism | en_US |
dc.subject | methylation | en_US |
dc.subject | Antigens, Neoplasm | en_US |
dc.subject | DNA Topoisomerases, Type II | en_US |
dc.subject | DNA-Binding Proteins | en_US |
dc.subject | Ellipticines | en_US |
dc.subject | Humans | en_US |
dc.subject | Intercalating Agents | en_US |
dc.subject | Methylation | en_US |
dc.subject | Topoisomerase II Inhibitors | en_US |
dc.title | Inhibition of human DNA topoisomerase II? by two novel ellipticine derivatives | en_US |
dc.type | Article | en_US |
dc.identifier.volume | 26 | en_US |
dc.identifier.issue | 7 | en_US |
dc.identifier.startpage | 1809 | |
dc.identifier.startpage | 1809 | en_US |
dc.identifier.endpage | 1812 | en_US |
dc.identifier.doi | 10.1016/j.bmcl.2016.02.034 | - |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.pmid | 26906637 | en_US |
dc.identifier.scopus | 2-s2.0-84979049924 | en_US |
dc.identifier.wos | WOS:000371344600033 | en_US |
dc.identifier.scopusquality | Q1 | - |
dc.owner | Pamukkale University | - |
item.languageiso639-1 | en | - |
item.fulltext | With Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.openairetype | Article | - |
item.grantfulltext | open | - |
crisitem.author.dept | 14.03. Basic Medical Sciences | - |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Files in This Item:
File | Size | Format | |
---|---|---|---|
10.1016 j.bmcl.2016.02.034.zip | 29.04 MB | Unknown | View/Open |
CORE Recommender
SCOPUSTM
Citations
35
checked on Nov 16, 2024
WEB OF SCIENCETM
Citations
30
checked on Nov 21, 2024
Page view(s)
48
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.